Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.59 |
| ▸ | PPP1R15A | O75807 | 1/20 | 0.59 |
| ▸ | MELK | Q14680 | 1/20 | 0.59 |
| ▸ | PPP1R15B | Q5SWA1 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32680261 | 1.00 | L3MBTL1 (0.59) | L3MBTL1PPP1R15AMELKPPP1R15BNPSR1 | |
| SCHEMBL2161103 | 1.00 | L3MBTL1 (0.59) | L3MBTL1PPP1R15AMELKPPP1R15BNPSR1 | |
| SCHEMBL534017 | 1.00 | L3MBTL1 (0.59) | L3MBTL1PPP1R15AMELKPPP1R15BNPSR1 | |
| Bicarbonate SCHEMBL11884724 | 0.92 | ALDH1A1 (0.54) | L3MBTL1PPP1R15AMELKPPP1R15BNPSR1 | |
| SCHEMBL534274 | 0.82 | GRIN2D (0.57) | L3MBTL1NPSR1ALDH1A1LMNAKMT2A | |
| SCHEMBL30862631 | 0.82 | GRIN2D (0.57) | L3MBTL1NPSR1ALDH1A1LMNAKMT2A | |
| SCHEMBL1776974 | 0.82 | GRIN2D (0.57) | L3MBTL1NPSR1ALDH1A1LMNAKMT2A | |
| SCHEMBL534275 | 0.82 | GRIN2D (0.57) | L3MBTL1NPSR1ALDH1A1LMNAKMT2A | |
| SCHEMBL6884832 | 0.81 | ALOX12 (0.55) | L3MBTL1PPP1R15AMELKPPP1R15BNPSR1 | |
| SCHEMBL7602955 | 0.81 | ALOX12 (0.55) | L3MBTL1PPP1R15AMELKPPP1R15BNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| EP-2413941-A1 | RENIN INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010114978-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-10-07 | — | — | WO | disclosed |
| EP-1423111-A4 | FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006064484-A1 | AZABICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-06-22 | — | — | WO | disclosed |
| US-7056924-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-7034046-B2 | NR1H4 nuclear receptor binding compounds | PHENEX PHARMACEUTICALS AG (DE) | 2006-04-25 | — | — | US | disclosed |
| US-7001909-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1583760-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | CV Therapeutics Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20040176383-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2004-09-09 | — | — | US | disclosed |
| WO-2004067506-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | CV THERAPEUTICS INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| EP-1423111-A1 | FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS | LION Bioscience AG (DE) | 2004-06-02 | — | — | EP | disclosed |
| US-20030187042-A1 | NR1H4 nuclear receptor binding compounds | PHENEX PHARMACEUTICALS AG (DE) | 2003-10-02 | — | — | US | disclosed |
| US-20030176447-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2003015771-A1 | FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS | LION BIOSCIENCE AG (DE) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176447-A1 | Substituted heterocyclic compounds | DLD, LPL, HDLBP | L3MBTL1 466/4885PPP1R15A 693/4885MELK 2199/4885 |
| US-20030187042-A1 | NR1H4 nuclear receptor binding compounds | NR1H4, NR1H2, NR1H3 | L3MBTL1 4354/4885PPP1R15A 3389/4885MELK 928/4885 |
| US-20040176383-A1 | Substituted heterocyclic compounds | DLD, LPL, HDLBP | L3MBTL1 466/4885PPP1R15A 693/4885MELK 2199/4885 |
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | L3MBTL1 4282/4885PPP1R15A 2318/4885MELK 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.